Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gumetinib plus albumin-bound docetaxel in MET-overexpressing or amplified advanced gastric/GEJ adenocarcinoma and other solid tumors
CTR20251576Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gumetinib, docetaxel in gastric cancer (GC), gastroesophageal junction adenocarcinoma, Nonhematologic neoplasms, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2025; status: active.
02
Drugs
gumetinibdocetaxel
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251576.